Health Catalyst Dirección

Dirección controles de criterios 3/4

El CEO de Health Catalyst es Dan Burton, nombrado en Oct 2012, tiene una permanencia de 12.08 años. posee directamente un 1.42% de las acciones de la empresa, con un valor de €6.74M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 7.5 años, respectivamente.

Información clave

Dan Burton

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	12.1yrs
Participación del CEO	1.4%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	7.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan Burton en comparación con los beneficios de Health Catalyst?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$79m
Jun 30 2024	n/a	n/a	-US$86m
Mar 31 2024	n/a	n/a	-US$106m
Dec 31 2023	n/a	n/a	-US$118m
Sep 30 2023	n/a	n/a	-US$124m
Jun 30 2023	n/a	n/a	-US$147m
Mar 31 2023	n/a	n/a	-US$148m
Dec 31 2022	US$4m	US$150k	-US$137m
Sep 30 2022	n/a	n/a	-US$151m
Jun 30 2022	n/a	n/a	-US$145m
Mar 31 2022	n/a	n/a	-US$147m
Dec 31 2021	US$6m	US$300k	-US$153m
Sep 30 2021	n/a	n/a	-US$147m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$126m
Dec 31 2020	US$5m	US$315k	-US$115m
Sep 30 2020	n/a	n/a	-US$86m
Jun 30 2020	n/a	n/a	-US$99m
Mar 31 2020	n/a	n/a	-US$181m
Dec 31 2019	US$4m	US$350k	-US$241m
Sep 30 2019	n/a	n/a	-US$304m
Jun 30 2019	n/a	n/a	-US$282m
Mar 31 2019	n/a	n/a	-US$190m
Dec 31 2018	US$5m	US$315k	-US$114m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Dan es razonable en comparación con empresas de tamaño similar en el mercado German.

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan Burton (49 yo)

12.1yrs

Permanencia

Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Burton	CEO & Director	12.1yrs	sin datos	1.42% € 6.7m
Jason Alger	Chief Financial Officer	less than a year	US$823.62k	0.19% € 890.9k
Benjamin Landry	General Counsel & Secretary of the Board	1.5yrs	US$946.31k	0.17% € 788.0k
Linda Llewelyn	Chief People Officer	6.8yrs	US$1.06m	0.026% € 125.2k
Daniel LeSueur	Chief Operating Officer	less than a year	sin datos	0.051% € 244.0k
Dave Ross	Chief Technology Officer	2.2yrs	sin datos	sin datos
Adam Brown	Senior Vice President of Investor Relations and Financial Planning & Analysis	3.8yrs	sin datos	sin datos
Amanda Flanders	Senior Vice President of Marketing & Communications	less than a year	sin datos	sin datos
Kyle Salyers	Chief Strategy Officer & Senior VP of Corporate Development	no data	sin datos	sin datos
Jeffrey Selander	Senior Vice President of International	5.5yrs	sin datos	sin datos
Holly Rimmasch	Senior VP & Chief Clinical Officer	no data	sin datos	sin datos
Leslie Falk	Chief Client Success Officer	no data	sin datos	sin datos

2.2yrs

Permanencia media

46yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2YP se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel Burton	CEO & Director	13.2yrs	sin datos	1.42% € 6.7m
John Kane	Independent Chairman	8.8yrs	US$316.16k	0.18% € 860.3k
Julie Larson-Green	Independent Director	4.8yrs	US$233.49k	0.076% € 362.1k
S. Smith	Independent Director	4.8yrs	US$237.25k	0.073% € 348.6k
Anita Pramoda	Independent Director	8.6yrs	US$244.77k	0.058% € 277.1k
Duncan Gallagher	Independent Director	7.5yrs	US$244.77k	0.092% € 438.2k
Matthew Kolb	Independent Director	1.3yrs	sin datos	sin datos

7.5yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de 2YP se considera experimentada (7.5 años de antigüedad promedio).

Health Catalyst Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Health Catalyst, Inc., Annual General Meeting, Jun 13, 2024

CEO & Director recently bought €188k worth of stock

Health Catalyst, Inc. Announces Board Changes, Effective March 1, 2024

Insufficient new directors

CEO & Director recently bought €460k worth of stock

Insufficient new directors

Recent updates

Health Catalyst Launches AI-Enabled Cyber Protection Product for Healthcare

Third quarter 2024 earnings released: US$0.24 loss per share (vs US$0.39 loss in 3Q 2023)

Health Catalyst, Inc. (NasdaqGS:HCAT) entered into an acquisition agreement to acquire Intraprise Health, LLC for $42.1 million.

New major risk - Share price stability

Health Catalyst, Inc. (NasdaqGS:HCAT) acquired Lumeon Limited for $65 million.

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.58 loss in 2Q 2023)

Health Catalyst, Inc. Provides Earnings Guidance for Second Half of 2024 and Reaffirm Earnings Guidance for 2025

Health Catalyst, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Health Catalyst, Inc. (NasdaqGS:HCAT) acquired Carevive Systems, Inc.

Health Catalyst, Inc Unveils Next-Generation Data and Analytics Ecosystem Built for Healthcare, Health Catalyst Ignite®

Health Catalyst, Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024

Health Catalyst, Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024

First quarter 2024 earnings released: US$0.35 loss per share (vs US$0.60 loss in 1Q 2023)

Health Catalyst, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Health Catalyst, Inc., Annual General Meeting, Jun 13, 2024

Health Catalyst, Inc. to Report Q1, 2024 Results on May 09, 2024

CEO & Director recently bought €188k worth of stock

Full year 2023 earnings released: US$2.09 loss per share (vs US$2.56 loss in FY 2022)

Health Catalyst, Inc. Announces Board Changes, Effective March 1, 2024

Health Catalyst, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Health Catalyst, Inc. (NasdaqGS:HCAT) acquired Electronic Registry Systems, Inc.

New minor risk - Share price stability

Health Catalyst, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.84 loss in 3Q 2022)

Health Catalyst, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$0.62 loss in 2Q 2022)

Health Catalyst, Inc. Provides Earnings Guidance for the Third Quarter of 2023

Health Catalyst, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Insufficient new directors

CEO & Director recently bought €460k worth of stock

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.42 loss in 1Q 2022)

Full year 2022 earnings released: US$2.56 loss per share (vs US$3.23 loss in FY 2021)

Health Catalyst, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Insufficient new directors

Health Catalyst, Inc. Announces Executive Changes

CEO & Director recently bought €1.9m worth of stock

Third quarter 2022 earnings released: US$0.84 loss per share (vs US$0.82 loss in 3Q 2021)

Health Catalyst, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Health Catalyst, Inc. Revises Earnings Guidance for the Full Year 2022

Health Catalyst, Inc.'s KPI Ninja Receives NCQA Measure Certification™ for HEDIS® Measurement Year 2022

Health Catalyst, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CEO & Director recently bought €1.0m worth of stock

Health Catalyst, Inc. Announces Executive Changes

Independent Director recently bought €174k worth of stock

Independent Director recently bought €174k worth of stock

CEO & Director recently bought €2.0m worth of stock

Health Catalyst, Inc. Announces Executive Appointments

Health Catalyst, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: US$0.62 loss per share (vs US$0.80 loss in 2Q 2021)

Health Catalyst, Inc. (NasdaqGS:HCAT) announces an Equity Buyback for $40 million worth of its shares.

Health Catalyst, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Health Catalyst, Inc.(NasdaqGS:HCAT) dropped from Russell 2000 Growth Index

First quarter 2022 earnings released: US$0.42 loss per share (vs US$0.65 loss in 1Q 2021)

Health Catalyst, Inc. (NasdaqGS:HCAT) acquired ARMUS Corporation.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Health Catalyst, Inc. Announces Revenue Guidance for the First Quarter and Full Year of 2022

Health Catalyst, Inc. (NasdaqGS:HCAT) entered into a definitive agreement to acquire KPI Ninja Inc.

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.68 loss in 3Q 2020)

Health Catalyst Unveils New Solution to Bring Clinical Research to Routine Healthcare

Chief Technology Officer recently sold €103k worth of stock

Health Catalyst, Inc. has completed a Follow-on Equity Offering in the amount of $224.999999 million.

Health Catalyst, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2021

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.71 loss in 2Q 2020)

Health Catalyst, Inc. Launches Value Optimizer - a New Approach to Managing Risk and Achieving Profitability in Population Health

Health Catalyst, Inc. (NasdaqGS:HCAT) entered into a definitive agreement to acquire Twistle, Inc. from Providence Ventures and others for approximately $170 million.

First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.47 loss in 1Q 2020)

Health Catalyst, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2021

Chair of the Board has left the company

Health Catalyst Launches New Healthcare.Ai™ to Deliver Augmented Intelligence At Scale to Healthcare Industry